Exelixis (EXEL) Convertible Debt (2010 - 2017)
Exelixis (EXEL) posted quarterly Convertible Debt of $113.3 million for Q1 2017, down 59.68% year-over-year from $281.2 million in Q1 2016, and up 39.09% quarter-over-quarter from $81.5 million in Q3 2016.
Analysis
Exelixis (EXEL) Convertible Debt (2010 - 2017) Analysis & Trends
Exelixis' Convertible Debt history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- In Q1 2017, Convertible Debt fell 59.68% year-over-year to $113.3 million; the TTM figure through Mar 2017 stood at $113.3 million (down 59.68% YoY), while the FY2015 annual figure was $337.9 million, up 51.12% from the prior year.
- Convertible Debt for Q1 2017 stood at $113.3 million, up from $81.5 million in the prior quarter.
- The five-year high for Convertible Debt was $337.9 million in Q4 2015, with the low at $81.5 million in Q3 2016.
- The 5-year median for Convertible Debt is $255.1 million (2013), against an average of $240.1 million.
- The sharpest annual moves came in 2013 and 2016: Convertible Debt soared 182.83% in 2013, then sank 72.6% in 2016.
- Exelixis' Convertible Debt stood at $301.6 million in 2013, then slipped by 25.84% to $223.6 million in 2014, then surged by 51.12% to $337.9 million in 2015, then tumbled by 75.89% to $81.5 million in 2016, then surged by 39.09% to $113.3 million in 2017.
- Business Quant data shows EXEL's Convertible Debt at $113.3 million in Q1 2017, $81.5 million in Q3 2016, and $288.6 million in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 113.35 Mn |
| Sep 30, 2016 | 81.49 Mn |
| Jun 30, 2016 | 288.56 Mn |
| Mar 31, 2016 | 281.16 Mn |
| Dec 31, 2015 | 337.94 Mn |
| Sep 30, 2015 | 297.44 Mn |
| Jun 30, 2015 | 291.23 Mn |
| Mar 31, 2015 | 284.36 Mn |
| Dec 31, 2014 | 223.63 Mn |
| Sep 30, 2014 | 177.96 Mn |
| Jun 30, 2014 | 173.64 Mn |
| Mar 31, 2014 | 261.41 Mn |
| Dec 31, 2013 | 301.55 Mn |
| Sep 30, 2013 | 248.71 Mn |
| Jun 30, 2013 | 242.46 Mn |
| Mar 31, 2013 | 236.39 Mn |
| Dec 31, 2012 | 291.83 Mn |
| Sep 30, 2012 | 239.24 Mn |
| Jun 30, 2012 | 85.86 Mn |
| Mar 31, 2012 | 83.58 Mn |